A combination of toripalimab and perioperative chemotherapy significantly extended EFS compared with chemotherapy alone among patients with resectable stage III non-small cell lung cancer, according to results of a randomized phase 3 study.
The findings of the Neotorch study, presented during an ASCO Plenary Series session, also showed the addition of toripalimab (Junshi Biosciences) to chemotherapy appeared well tolerated, with no new safety signals and a manageable safety profile.
“The toripalimab arm also demonstrated higher [major pathologic complete response] and [pathologic complete